Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Melanie Davies CBE, MB ChB, MD, FRCP, FRCGP, FMedSci

Melanie J. Davies CBE, MB ChB, MD, FRCP, FRCGP, FMedSci

Professor of Diabetes Medicine, Diabetes Research Centre, University of Leicester, Leicester, United Kingdom

Melanie Davies is Professor of Diabetes Medicine at the University of Leicester and an Honorary Consultant Diabetologist at the University Hospitals of Leicester NHS Trust. She is the Co-Director of the Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust.

Professor Davies’ research interests include the causes, screening, prevention, self-management and treatment of type 2 diabetes mellitus.She is a National Institute for Health Research Senior Investigator Emeritus and Director of the NIHR Leicester Biomedical Research Centre and co-chair of EASD/ADA’s Consensus Report on T2DM Management.

Professor Davies has published over 910 original articles and has over £100M of grant funding. She was awarded the CBE (Commander of the Most Excellent Order of the British Empire) in the 2016 New Year’s Honour’s List for services to diabetes research.


Professor Melanie Davies has acted as consultant, advisory board member and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi, an advisory board member for Pfizer, and Zealand Pharma and a speaker and advisory board member for AstraZeneca. She has received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen and Sanofi-Aventis and Eli Lilly.

Recent Contributions to PracticeUpdate:

  1. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes